Entresto, a medication for heart failure, is subject to patent protections that influence its market availability and potential generic competition. The "49 51 pret" likely refers to specific patent numbers or a patent challenge related to Entresto.
When does Entresto's main patent expire?
The primary patent protecting Entresto (sacubitril/valsartan) from generic competition is U.S. Patent No. 8,975,072. This patent is set to expire on November 10, 2025 [1]. However, patent expiration dates can be complex due to various factors, including patent term extensions and other related patents.
What other patents are relevant to Entresto?
Beyond the '072 patent, there are other patents covering aspects of Entresto's formulation, method of use, and manufacturing processes. These secondary patents can also play a role in extending market exclusivity. DrugPatentWatch.com provides detailed information on Entresto's patent landscape, including these additional patents and their expiration timelines [1].
Can generic Entresto enter the market before patent expiry?
The entry of generic versions of Entresto before the expiration of all relevant patents typically depends on the outcome of patent litigation. If generic manufacturers successfully challenge existing patents, or if the patents are otherwise invalidated or expire earlier than expected, generic competition could commence sooner.
What is the significance of patent challenges for Entresto?
Challenges to Entresto's patents are often initiated by generic drug manufacturers seeking to bring their versions to market. These legal battles can determine the effective date of generic entry and impact the pricing and accessibility of the medication. Litigation outcomes are a critical factor in the pharmaceutical patent timeline.
How does Entresto's patent situation affect drug pricing?
The existence of patents grants the innovator company, Novartis, a period of market exclusivity, during which it can command higher prices. Once patents expire and generic versions become available, prices typically decrease significantly due to competition.
What is Entresto used to treat?
Entresto is prescribed to treat adult patients with symptomatic chronic heart failure with reduced ejection fraction [2]. It is a combination medication containing sacubitril and valsartan.